Literature DB >> 23380865

Outcomes after liver transplantation in patients achieving a model for end-stage liver disease score of 40 or higher.

Sophoclis Alexopoulos1, Lea Matsuoka, Yong Cho, Elizabeth Thomas, Mohd Sheikh, Maria Stapfer, Kiran Dhanireddy, Linda Sher, Rick Selby, Yuri Genyk.   

Abstract

BACKGROUND: Patients with Model for End-Stage Liver Disease (MELD) scores of 40 or higher are at high risk for liver transplantation. In some regions, the organ donor shortage has resulted in a substantial increase in the number of patients who underwent transplantation with MELD scores of 40 or higher. The objective of this study was to characterize the outcomes of liver transplantation in these patients.
METHODS: A single-center retrospective study evaluating the outcome of liver transplantation in 38 consecutive patients achieving a MELD score of 40 or higher from January 1, 2006, to November 30, 2010, was conducted. Patient and graft survivals and independent risk factors for postoperative death or graft loss were determined.
RESULTS: Kaplan-Meier-based 1-, 2-, and 3-year patient survival rates were 89%, 82%, and 77% with 1-, 2-, and 3-year graft survival rates of 84%, 75%, and 70.3%, respectively. One of three recipients was on a vasopressor before transplantation, and 13% were mechanically ventilated. Renal replacement therapy was used before operation in 90% of the recipients. Postoperative length of stay averaged 38 days. There was a 42% incidence of postoperative bacteremia and an 18% incidence of bile duct stricture within 6 months. Univariate analysis identified admission-to-transplantation time and recipient diabetes as risk factors for graft failure and patient death. Multivariate analysis confirmed recipient diabetes as a risk factor for patient survival and admission-to-transplantation time of more than 15 days as a risk factor for graft survival.
CONCLUSIONS: Acceptable outcomes are achievable after liver transplantation in patients with MELD scores of 40 or higher but come at high pretransplantation and posttransplantation resource utilization.

Entities:  

Mesh:

Year:  2013        PMID: 23380865     DOI: 10.1097/TP.0b013e3182751ed2

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score ≥ 40: A retrospective cohort study.

Authors:  Filipe S Cardoso; Constantine J Karvellas; Norman M Kneteman; Glenda Meeberg; Pedro Fidalgo; Sean M Bagshaw
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

2.  Survival outcomes in liver transplant recipients with Model for End-stage Liver Disease scores of 40 or higher: a decade-long experience.

Authors:  Hina J Panchal; Joel B Durinka; Jeromy Patterson; Farah Karipineni; Sarah Ashburn; Eric Siskind; Jorge Ortiz
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

3.  Single-Center Experience on Liver Transplantation for Model for End-Stage Liver Disease Score 40 Patients.

Authors:  Georgios C Sotiropoulos; Spyridon Vernadakis; Andreas Paul; Dieter P Hoyer; Fuat H Saner; Anja Gallinat
Journal:  Dig Dis Sci       Date:  2016-08-18       Impact factor: 3.199

4.  Staged Biliary Reconstruction After Orthotopic Liver Transplantation: A Practical Surgical Strategy for High-Acuity Adult Recipients.

Authors:  Terra Pearson; Michael A Zimmerman; Joohyun Kim; Patrick A Palines; Calvin M Eriksen; Melissa Wong; Motaz A Selim; Daniela Markovic; Johnny C Hong
Journal:  Transplant Direct       Date:  2019-08-08

Review 5.  Portal flow modulation in living donor liver transplantation: review with a focus on splenectomy.

Authors:  Tomoharu Yoshizumi; Masaki Mori
Journal:  Surg Today       Date:  2019-09-25       Impact factor: 2.549

6.  Outcomes of liver transplant recipients with high MELD scores: an experience from a Canadian centre.

Authors:  Michael S Bleszynski; Subin Punnen; Sameer Desai; Trana Hussaini; Vladimir Marquez; Eric M Yoshida; Saumya Jayakumar; Stephanie Chartier-Plante; Maja Segedi; Charles H Scudamore; Stephen Chung; Andrzej K Buczkowski; Peter T W Kim
Journal:  Can J Surg       Date:  2022-07-05       Impact factor: 2.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.